메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies

[ 메디채널 김갑성 기자 ] SAN FRANCISCO and SUZHOU, China, Dec. 5, 2025 -- Innovent Biologics (HKEX: 01801) today announced that the global strategic collaboration with Takeda (TSE: 4502, NYSE: TAK) has closed and become effective following the satisfaction of all closing conditions. The collaboration, initially announced on October 22, 2025, aims to accelerate the global development and commercialization of Innovent's next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, including the global partnership on IBI363 (PD-1/IL-2α-bias) and IBI343 (CLDN18.2 ADC), and an option
- 김갑성 기자
- 2025-12-05 07:38
Renuka Iyer, MD, Named New Chief Medical Officer for National Comprehensive Cancer Network (NCCN)

[ 메디채널 김갑성 기자 ] Acclaimed oncologist from Roswell Park Comprehensive Cancer Center to help lead nonprofit responsible for gold standard guidelines that define and advance cancer care worldwide. PLYMOUTH MEETING, Pa., Dec. 4, 2025 -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers that publishes free evidence-based, expert consensus-driven guidelines for cancer prevention and care—today announced the hiring of Renuka Iyer, MD, as the new Chief Medical Officer (CMO) for the organization. Dr. Iyer has a long history of lead
- 김갑성 기자
- 2025-12-04 21:04
레누카 아이어 박사, NCCN 최고 의료 책임자로 선임

[ 메디채널 김갑성 기자 ] 로스웰파크 종합암센터의 저명한 종양학 전문의가 전 세계 암 치료 표준을 정립하고 개선하는 비영리 단체인 NCCN을 이끌 예정이다. 플리머스 미팅, 펜실베이니아주, 2025년 12월 4일 -- 미국 국립종합암센터네트워크(National Comprehensive Cancer Network®, NCCN®)가 오늘 레누카 아이어(Renuka Iyer) 박사를 신임 CMO로 선임했다고 발표했다. NCCN은 내로라하는 암 전문 병원들의 연합체로서 암 예방 및 치료에 관한 증거 기반의 무료 암 치료 가이드라인을 발간하고 있다. 아이어 박사는 오랫동안 종양학 분야의 선구자이자 혁신가로 활약해 왔다. 아이어 박사는 현재 NCCN 회원 기관인 [ 메디채널 김갑성 기자 ] 로스웰파크 종합암센터(Roswell Park Comprehensive Cancer Center)의 종양학 교수이자 위장관 종양학과장, 로스웰파크 의학부(Roswell Park's Department of Medicine) 교수 인사 담당 부처장, 그리고 로스웰파크 케어네트워크(Roswell Park Care Networ
- 김갑성 기자
- 2025-12-04 21:04
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO

[ 메디채널 김갑성 기자 ] Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistance The Phase 1 ragistomig study achieved its objective, as the new Q6W extended dosing interval produced strong anti-tumor efficacy in PD-L1-non-responders, with an improved safety profile The interim results, including immunological data on CD8+ cell proliferation and memory T-cell activation, are expected to be presented in a poster session at ESMO-IO on December 10, 2025
- 김갑성 기자
- 2025-12-04 20:34
Hope Medicine Inc.'s HMI-115 Received U.S. FDA Fast Track Designation, Accelerating Global Development

[ 메디채널 김갑성 기자 ] HMI-115 received FDA Fast Track Designation based on results from a Phase II clinical trial for endometriosis Mean dysmenorrhea pain score reduced by 42% Mean non-menstrual chronic pelvic pain score reduced by 52% Most patients maintained normal menstrual cycles No typical peri-menopausal symptoms were reported in patients No significant changes in bone mineral density or sex hormone levels SHANGHAI, Dec. 4, 2025 -- Hope Medicine Inc. ("HopeMed"), a clinical-stage innovative biopharmaceutical company, today announced that i
- 김갑성 기자
- 2025-12-04 20:08
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics

Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets and China Collaboration designed to accelerate and expand the development of synergistic combinations with CR-001 and ADCs, including SKB105 CR-001 and SKB105 on track to enter Phase 1/2 monotherapy clinical trials in Q1 2026 with combination studies to follow CHENGDU, China and WALTHAM, Mass., Dec. 4, 2025 -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", 6990.HK), which focuses on
- 김갑성 기자
- 2025-12-04 19:50
Clarivate Presents Cortellis Regulatory AI Assistant to Cut Through Complexity in Safety and Compliance

Powered by agentic AI, new features help regulatory teams improve accuracy and enable faster, more confident decisions across the product lifecycle LONDON, Dec. 4, 2025 -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has launched its Cortellis Regulatory Intelligence AI Assistant. Powered by agentic AI, the assistant introduces new capabilities that redefine how life sciences professionals access and apply regulatory information. Following a successful beta release earlier this year, the assistant is now available to all Cortellis Regulat
- 김갑성 기자
- 2025-12-04 16:00
UMED Wins CES Innovation Awards® 2026, Redefining Bladder Care with World's First Automated Irrigation System

[ 메디채널 김갑성 기자 ] Transforming bladder care from hospital-centered procedures to accessible, data-driven digital urology SEOUL, South Korea, Dec. 4, 2025 -- UMED Inc, an AI-driven urology-focused healthcare startup, announced that its automated bladder irrigation system, UroRinse™ Light, has been named as a CES Innovation Awards® Honoree in the Digital Health category. UroRinse™ Light will be showcased at CES 2026 Eureka Park (Booth #62501-31). A Breakthrough Recognized on the Global Stage Hosted by the Consumer Technology Association (CTA), CES is the world's
- 김갑성 기자
- 2025-12-04 15:08
Menarini Asia-Pacific Expands Production Facilities, Strengthening Indonesia's Role as Regional Manufacturing Hub

Menarini announces the expansion of MiLab facilities in Cikarang, including a new warehouse and enhanced production facility to meet growing export demands. Another milestone includes the projected export of up to 700,000 units of Dermatix products to China alone this year. The event highlights Menarini's collaboration with the Indonesian government to position the country as a key regional pharmaceutical hub. JAKARTA, Indonesia, Dec. 4, 2025 -- Leading European biopharmaceutical company, Menarini Asia-Pacific ("Menarini"), announced the expansion of i
- 김갑성 기자
- 2025-12-04 14:30
HiroPharmaConsulting (R) Granted Patent for AI-enabled Reliability Assurance Method for Pharmacovigilance Systems

OSAKA, Japan, Dec. 4, 2025 -- HiroPharmaConsulting (R) Co., Ltd. announced that it has received a patent for an innovative Good Pharmacovigilance Practice (GVP) Computerized System Validation (CSV) methodology designed to ensure the reliability of pharmacovigilance systems equipped with AI functions. This patent represents Japan's first intellectual property specifically dedicated to the reliability assurance of AI-enabled pharmacovigilance systems. The Japan Patent Office has officially recognized the invention's novelty and inventive step, underscoring its significance as a breakthrough in
- 김갑성 기자
- 2025-12-04 14:00

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2026-01-01_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 01일 22시 40분